. 2019 Jan 16;104(6):2216–2228. doi: 10.1210/jc.2018-02289

Table 8.

Thyroid Function Tests and HbA1c in Lipodystrophy and INSR Mutation Groups Based on Metreleptin Treatment

	Never on Leptin (n = 32)	On Leptin (n = 60)	P Value
TSH, μIU/mL (range); n	1.8 ± 1 (0.58–5.05);	1.9 ± 1.3 (0.37–6.08);	0.8
TSH, μIU/mL (range); n	n = 28	n = 57	0.8
fT4, ng/dL (range); n	1.2 ± 0.4 (0.8–1.9);	1.2 ± 0.2 (0.9–1.7);	0.3
fT4, ng/dL (range); n	n = 8	n = 46	0.3
TT4, μg/dL (range); n	7.5 ± 2.3 (4.7–15);	8 ± 1.9 (5.3–11.7);	0.1
TT4, μg/dL (range); n	n = 17	n = 12	0.1
TT3, ng/dL (range); n	112 ± 27 (71–164);	127 ± 37 (93–219);	0.2
TT3, ng/dL (range); n	n = 19	n = 12	0.2
Positive antithyroid antibodies,^a %; n	23; n = 22	36; n = 50	0.9
HbA1c, % (range	6.7 ± 1.8 (4.4–11);	7.5 ± 2.5 (4.3–13.3);	0.2
HbA1c, % (range	n = 28	n = 59	0.2

^{^a}

Antithyroid antibodies were checked at any time point.